Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Study design<br />
• Tocilizumab or placebo q4wk iv (6 infusions) maintaining stable dose of MTX<br />
• Total randomised: 623 patients<br />
• Early withdrawals and patients entering escape were classified as non-responders<br />
for the ACR and <strong>EULAR</strong> analyses<br />
TCZ 4 mg/kg +<br />
MTX (n=214)* ,§<br />
TCZ 8 mg/kg +<br />
MTX (n=205)<br />
Placebo + MTX<br />
(n=204) 0 2 4 6 8 10 12 14 16 18 20 22 24<br />
* One patient was randomised to tocilizumab 4 mg/kg + MTX but was not dosed<br />
§Includes one patient who was randomised to tocilizumab 4 mg/kg + MTX but who received tocilizumab 8 mg/kg + MTX through study<br />
17